Acute Kidney Transplant Rejection After Administration of Nivolumab in a Dialysis Patient With a Failed Graft

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review

“…Histopathological evaluation following transplant nephrectomy revealed chronic active T-cell-mediated rejection. Another similar report by Duni et al [ 49 ] describes a single case of kidney graft rejection of a long-term nonfunctioning graft 14 days after the first cycle of therapy with PD-1 inhibitor (nivolumab) in a patient receiving PD for >3 years. On the other hand, a report of 19 dialysis patients who received ICI therapy between 2013 and 2019 showed that although 32% of the patients experienced diverse irAEs, none of the 4 patients with prior failed kidney allografts included in the study demonstrated clinical evidence of rejection [ 5 ].…”

Nephrotoxicity of combination drug therapy in metastatic renal cancer

“…На настоящий момент однозначно сложно делать выводы о прогнозе для пациентов с терминальной стадией ХБП на фоне иммунотерапии злокачественного новообразования. Необходимо проводить дальнейшие исследования в данной группе для получения более репрезентативных выборок и оценки прогноза в зависимости от гистологического типа опухоли [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37].…”